MarketPulse

rare skin diseases

3 articles
The Motley FoolThe Motley Fool··Jonathan Ponciano

Palvella Stock Soars 340% as COO Executes Pre-Planned Share Sale

Palvella COO sells ~$508K in shares via pre-planned trading arrangement amid 340% annual surge, driven by strong Phase 3 QTORIN rapamycin data and upcoming NDA submission.
PVLAbiotechclinical-stage
GlobeNewswire Inc.GlobeNewswire Inc.··Not Specified

Palvella Therapeutics Secures $200M in Upsized Share Offering

Palvella Therapeutics raised $200M through upsized share offering to fund clinical development of rare disease therapies including skin disease and vascular malformation treatments.
PVLAclinical-stagepublic offering
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Palvella to Present Phase 3 QTORIN Trial Results for Lymphatic Malformations

Palvella to present Phase 3 SELVA trial results for QTORIN gel treating lymphatic malformations on February 24, 2026, with data release at 6:30 a.m. ET.
PVLAPhase 3 clinical trialFDA approval